Podcasts about Progression

Pivot Family! We are out here in Salt Lake City checking out a whole new world for us as we are on site for the 2025 X Games! As the X Games get underway, The Pivot Podcast sits down with two of the most explosive names in action sports — Ryan Williams, the BMX innovator pushing the limits of what's possible, and Dashawn Jordan, the street skater known for his power, precision, and style. Two completely different approaches to each's sport, but unified by the same goal- compete to win. Ryan, Channing and Fred get introduced to the extreme side of action sports, the high risk-high reward mentality and the laser focus needed to lock in on the one opportunity that measures success or failure. We talk mindset, motivation, and mayhem — from landing never-been-done tricks to staying locked in under pressure. Ryan and Dashawn open up about their journeys, what it takes to stay at the top, and what fans can expect at this year's X Games. Whether it's the mega ramp or the street course, these athletes are ready to redefine progression. Don't miss this raw and real conversation with two athletes redefining their sports and giving us a glimpse of what it takes to compete at the highest level. Comment and let us know what you think! Learn more about your ad choices. Visit megaphone.fm/adchoices

In Colorado, Barry Morphew is arrested for the second time for the murder of his wife, Suzanne, who disappearedon Mother's Day in2020. In Bowling Green, Kentucky, two men go on trial for the murder of mom Crystal Rogers. Updates on Monica Sementilli and former MLB pitcher Dan Serafini. Plus, we've all seen age-progressedimagesofmissingchildren — can they actually help?See more of Dateline's reporting on missing persons cases in which age-progressed images are featuredhere:https://www.nbcnews.com/age-progressionsFind out more about the cases covered each week here:www.datelinetruecrimeweekly.com

Much of the scientific process involves searching. But rather than continue to rely on the luck of discovery, Google DeepMind has engineered a more efficient AI agent that mines complex spaces to facilitate scientific breakthroughs. Sarah Guo speaks with Pushmeet Kohli, VP of Science and Strategic Initiatives, and research scientist Matej Balog at Google DeepMind about AlphaEvolve, an autonomous coding agent they developed that finds new algorithms through evolutionary search. Pushmeet and Matej talk about how AlphaEvolve tackles the problem of matrix multiplication efficiency, scaling and iteration in problem solving, and whether or not this means we are at self-improving AI. Together, they also explore the implications AlphaEvolve has to other sciences beyond mathematics and computer science. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @pushmeet | @matejbalog Chapters: 00:00 Pushmeet Kohli and Matej Balog Introduction 0:48 Origin of AlphaEvolve 02:31 AlphaEvolve's Progression from AlphaGo and AlphaTensor 08:02 The Open Problem of Matrix Multiplication Efficiency 11:18 How AlphaEvolve Evolves Code 14:43 Scaling and Predicting Iterations 16:52 Implications for Coding Agents 19:42 Overcoming Limits of Automated Evaluators 25:21 Are We At Self-Improving AI? 28:10 Effects on Scientific Discovery and Mathematics 31:50 Role of Human Scientists with AlphaEvolve 38:30 Making AlphaEvolve Broadly Accessible 40:18 Applying AlphaEvolve Within Google 41:39 Conclusion

In Colorado, Barry Morphew is arrested for the second time for the murder of his wife, Suzanne, who disappeared on Mother's Day in 2020. In Bowling Green, Kentucky, two men go on trial for the murder of mom Crystal Rogers. Updates on Monica Sementilli and former MLB pitcher Dan Serafini. Plus, we've all seen age-progressed images of missing children — can they actually help?See more of Dateline's reporting on missing persons cases in which age-progressed images are featured here: https://www.nbcnews.com/age-progressions Find out more about the cases covered each week here: www.datelinetruecrimeweekly.com

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Toronto Blue Jays Infielder and Outfielder Addison Barger joined OverDrive to discuss his impressive season with the Blue Jays, the experience throughout the start at bat, playing the guitar, the atmosphere of the team, his approach with power, his strength towards the top of the lineup and more.

Hey everyone! Alex and KJ dive into the Packers-Bears rivalry in today's show after Caleb Williams got it going over the weekend. The brothers also touch on the roster, division competition, and more. Welcome Back to the IKE Packers Podcast!Help the show by telling another Packers fan! Other ways to contribute are by leaving a 5-star review on Apple Podcasts and subscribing wherever you get your podcasts.@IKE_Packers on X

In this episode of the Transform Sales Podcast: Sales Software Review Series, Dave Menjura

TSN Soccer Reporter Matthew Scianitti joined OverDrive to discuss the headlines around CONCACAF's investigation in Jesse Marsch for his incidents at the Gold Cup, his ferocious character on the sideline, Canada Soccer's team foundation, the relationship with Alphonso Davies, the future of the organization and more.

Send us a textNo medal. No crowd. No finish line. So why keep pushing?In this episode of Running with James, we're flipping the script on off-season training and tackling the myth that you need a race to stay motivated. Because real athletes don't just train for events—they train for growth.James and the crew share how they stay locked in when there's nothing on the calendar, and why some of the biggest gains—physically and mentally—come when no one's watching.You'll learn:•Why training without pressure can lead to massive breakthroughs•How to build a champion's mindset even in the off-season•The difference between being goal-driven and race-dependent•Simple ways to set purpose-filled targets between racesIf you want to level up this fall, the work starts now. Race or no race. Fit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts SpotifySupport the showBecome a member and support the show:https://patreon.com/RunningwithJames?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator&utm_content=join_link

When High Conflict Takes You By SurpriseLife can change dramatically when you unexpectedly encounter a person who demonstrates high conflict behavior. Bill Eddy and Megan Hunter from the High Conflict Institute in Scottsdale, Arizona, explore the unsettling experience of being blindsided by high conflict situations—whether in a new job, relationship, or family dynamic.Understanding the Impact of Unexpected High ConflictWhen high conflict behavior emerges unexpectedly, it often creates a destabilizing ripple effect. The initial confusion and self-doubt can leave anyone questioning their capabilities and judgment. This episode examines how these situations develop, from the early stages of confusion through the progression of mounting tension and isolation.Recognizing High Conflict PatternsThe most challenging aspect of surprise high conflict situations is their ability to create self-doubt in even the most confident individuals. What begins as an attempt to improve communication or performance often escalates into a pattern of increasing criticism and isolation. Understanding these patterns helps identify when you're dealing with high conflict behavior rather than typical workplace or relationship challenges.Questions We Answer in This EpisodeHow do you recognize when self-doubt stems from high conflict behavior?What makes group high conflict situations especially challenging?Why do attempts to "try harder" often backfire with high conflict people?How can you protect yourself from high conflict surprises?Key TakeawaysRemember "It's not about me" when facing unexpected criticism90% of people don't engage in high conflict behaviorPhysical distance can help manage high conflict situationsTrust your experience with non-high conflict relationshipsSetting clear limits with consequences can be effectiveHigh conflict surprises can happen to anyone, anywhere. This episode provides practical insights for recognizing, understanding, and managing these challenging situations while maintaining your confidence and perspective.Additional ResourcesExpert PublicationsIt's All Your Fault at Work! Dealing with Narcissists and Other High-Conflict People - Managing High Conflict Workplace Dynamics5 Types of People Who Can Ruin Your Life - Understanding High Conflict BehaviorProfessional DevelopmentNew Ways for Couples & Families: Online relationship strengthening courseConflictInfluencer.com: Advanced conflict management training (Coming Soon)Connect With UsVisit High Conflict Institute: highconflictinstitute.comSubmit questions for Bill and MeganBrowse our complete collection of books and resources in our online store—available in print and e-book formatsFind these show notes and all past episode notes on our websiteImportant NoticeOur discussions focus on behavioral patterns rather than diagnoses. For specific legal or therapeutic guidance, please consult qualified professionals in your area. (00:00) - Welcome to It's All Your Fault (01:32) - High Conflict Surprises (02:37) - Updates (03:32) - Bill's Example (09:07) - What Happens In Our Minds (11:03) - Progression and Impact (13:02) - CARS Method (20:23) - Recentering Yourself (23:59) - New on the Job (26:08) - High Conflict Traps (27:19) - Target of Blame (29:00) - Larger Groups (31:42) - Wrap Up (32:44) - Reminders Learn more about our New Ways for Work Coaching sessions. Get started today!

After 25+ years in property investment, Arsh has made a controversial decision that's going against everything the "scale at all costs" mentality teaches.   While everyone's chasing their next deal, he's saying NO to new acquisitions. Why? Because he's learned that MORE properties often means MORE problems, not more freedom.   His HMO friend in the Midlands regrets scaling too big Tenant issues, rent arrears, and endless legislation The "acquisition drug" that keeps us buying when we should be optimizing   Sometimes the most powerful word in property is "NO."   Take a moment to reassess where you are in your property journey. What issues are you facing? How are they being dealt with? Sometimes scaling back creates more freedom than scaling up.   Join the Property Investor App WhatsApp Channel: bit.ly/PIAWhats   Book Your 1 Hour Call with Arsh here: http://bit.ly/1HourPropertyCoach   Wanna connect with Arsh? Click this link: www.arshellahi.com/contact   Want to know more about the Property Rebel? Head over to Arsh's Youtube Channel. Where you can find lots more quality content and information. Click To Subscribe   Have you heard about Arsh's app the Property Investor? You can download it directly to your mobile by clicking the links below:   Apple Devices: Download Here   Android Devices: Download Here   Or Visit the website by clicking HERE   Thank you for listening! #propertyrebel

Damien and Ali get In The Conversation about new holidays, Father's Day reflection, and having something to do. Twitter.com/dlemoncomedy // Twitter.com/mrmuhammad Keep up with the conversation on Instagram www.instagram.com/intheconversation

On this week's theme episode of the Massively OP Podcast, Bree and Justin talk all about character progression in MMOs! Trust us, there are far more types of progression than you might first assume -- and we're going to try to cover as many of them as we can in an hour. Plus. Plus about fifteen. It's the Massively OP Podcast, an action-packed hour of news, tales, opinions, and gamer emails! And remember, if you'd like to send in your question to the show, use this link. Show notes: Intro What is character progression? Why is progression important? The broad categories of progression Horizontal vs vertical progression Story as progression Offline progression Rebirth progression Progression you can lock Crafting XP progression PvP progression Collaborative progression Reward tracks and mastery system Gearscore Money/collections Dungeon progression Outro Other info: Podcast theme: "Irontoe 2006" from EverQuest II Your show hosts: Justin and Bree Listen to Massively OP Podcast on iTunes, Stitcher, Player FM, TuneIn, iHeartRadio, Pocket Casts, Amazon, and Spotify Follow Massively Overpowered: Website, Twitter, Facebook, Twitch If you're having problems seeing or using the web player, please check your flashblock or scriptblock setting.

In this episode, Camila returns to Grief Out Loud six years after her first appearance to share how grief continues to evolve. What began with the sudden loss of her mother at age 21 has now expanded to include the ongoing grief of caregiving for her father, who is living with dementia and Alzheimer's disease.  Camila discusses the unique challenges of long-distance caregiving, the differences between sudden loss and gradual decline, and how these two types of grief intersect in her life. She also discusses navigating major life milestones—including getting married during the pandemic—without her mother's presence.  We Discuss: The difference between sudden loss and the "slow grief" of watching a parent decline  How grief has shifted in the 15+ years since her mother's unexpected death Losing her father as the co-archivist of her mother's life and their family history Managing long-distance caregiving The failures of the elder care system in the U.S. The role of chosen family and support Wedding planning and the question of how to honor her mother's memory  The complexity of being a queer person in traditionally heteronormative grief support spaces  Feeling like she no longer has parents, even though her father is still alive  The therapeutic value of pets  Finding moments of connection and joy with her father despite his condition  Using poetry as a processing tool for grief  About the Guest:  Camila is a poet who has published three books of poetry:  The Progression of Grief (about losing her mother)  New Waters (about falling in love and healthy relationships)  The Longevity of Grief (about caring for her father and how different types of grief intersect) This episode is the third in our 2025 three-part series highlighting the voices of communities who have historically been underrepresented in the grief world. The series is part of an ongoing collaboration between Dougy Center and The New York Life Foundation. We are deeply grateful for New York Life Foundation's tireless support and advocacy for children and teens who are grieving. Grief Out Loud is a production of Dougy Center, the National Grief Center for Children and Families in Portland, Oregon.

Ever go into the gym, lift weights, and wonder if you are actually making progress? You are not alone. One of the most common questions I get is how to know when it is the right time to increase weight, add reps, or push harder in a workout. The truth is, most people are just guessing, which leads to randomness and stalled results. In this episode, I break down a simple strategy we use with our clients at Fit for Life Academy called dynamic double progression. It takes the guesswork out of training by giving you a clear and flexible system to track your progress and know exactly when to make adjustments. We cover why progressive overload is essential, what it really means to do more over time, and how to apply this system to your own workouts to build strength and muscle consistently. If you have ever felt stuck or unsure whether you are training effectively, this episode will give you the clarity and structure you need to move forward with confidence. Tune in and start making every workout count. Download my FREE Nutrition for Fat Loss eBook:  https://fit4lifeacademy.health/blueprint Apply to work with us at Fit4Life Academy: https://fit4lifeacademy.health/vsl-page I can't wait to hear your thoughts on this episode. Stay healthy and inspired.

Emission spéciale du 15 juin 2025: Trump-Poutine: Ils veulent tuer l'Europe.Jean-Noël Barrot, Ministre de l'Europe et des Affaires étrangères. Depuis le discours violent de JD Vance à Munich, est-ce que la ligne entre le quai d'orsay et Washington est coupée? Quid des sanctions promises faute de cessez le feu par le président Macron et l'Europe? Quel est le poids de l'Europe face aux Russes et à la guerre commerciale lancée par Trump? C'est un entretien exclusif mené par Caroline Roux.

durée : 00:25:08 - Jonas Vitaud, pianiste (3/5) - par : Judith Chaine - Pianiste reconnu, formé au CNSM de Paris, Jonas Vitaud excelle en récital, en musique de chambre et dans le répertoire contemporain, notamment avec Dutilleux et Kurtág. Un entretien riche sur son parcours, ses choix artistiques et sa vision de la musique au micro de Judith Chaine. - réalisé par : Adrien Roch

CHP welcomes guest minister Dr. Tim Hill.

The Denver Broncos' offseason program is over.Did Bo Nix perform above or below expectations? Which receivers were his top targets? Was Que Robinson or RJ Harvey the Denver Broncos' top rookie? Who needs to step up in training camp?The guys break down all of the biggest lessons from the Denver Broncos' OTAs and minicamp.In honor of Friday the 13th, the guys draft the scariest Denver Broncos in team history.On the DNVR Broncos Podcast, Zac Stevens, Ryan Koenigsberg and Henry Chisholm are coming to you LIVE from the DNVR Bar to break down all of the latest news in Broncos Country. Start: 0:00Biggest takeaway from the offseason so far: 5:15Bo Nix's improvement: 13:11Defense improvement: 19:56Offseason takeaways from rookies: 33:20Friday draft: 52:00 An ALLCITY Network Production PARTY WITH US: https://thednvr.com/events ALL THINGS DNVR: https://linktr.ee/dnvrsports BALL-KNOWER BONUS/Merch: https://promotion.allcitynetwork.com/promotions/store.allcitynetwork/7d48d294-4260-4bac-aca1-9a18eef8ca78 SUBSCRIBE: https://www.youtube.com/c/DNVR_Sports Toyota: Visit Your Front Range Toyota Stores at a location near you - Toyota is the official vehicle of DNVR. Toyota - Let's Go Places! Toyota Drive to the Playoffs: https://kse.jotform.com/250624177000950?camefrom=CFC_KSE_xJZqkfEGc0GvJpltfPs0pA&utm_[…]um=xJZqkfEGc0GvJpltfPs0pA&utm_campaign=xJZqkfEGc0GvJpltfPs0pA First Bank: So, if you're ready for better banking and the chance to earn a little extra, head to efirstbank.com/bonus. Certain restrictions and requirements apply. Member FDIC. Hall of Fame App: Get a 7-Day Free Trial + 50% Off your first month with code DNVR. Just download the HOF app on iOS and Android or visit www.hofbets.com, enter code DNVR, and you're all set. #ad Raising Cane's Rooftop Fridays: https://thednvr.com/event/friday-rooftop-club-at-coors-field-presented-by-raising-canes/   Monarch Money: Use Monarch Money to get control of your overall finances with 50% off your first year at https://www.monarchmoney.com/dnvr  bet365: Go to https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLERUCHealth: Learn more about Living Like There's A Tomorrow at https://www.uchealth.org/tomorrow/?utm_source=DNVR&utm_medium=Audio&utm_campaign=Brand_LLTIAT_Null_JFMFY25_AW_Null Empire Today: Schedule a free in-home estimate today! All listeners can receive a $350 OFF discount when they use the promo code DNVR. Restrictions apply. See https://empiretoday.com/dnvr for details Coors Light:  Delivery on Instacart at https://coorslight.com/DNVR. Celebrate Responsibly. Coors Brewing Company, Golden, Colorado. Gametime: Download the app, create an account, and use code DNVR for $20 off your first purchase. Terms apply. Shady Rays: Head to https://shadyrays.com and use code: DNVR for 35% off polarized sunglasses. Try for yourself the shades rated 5 stars by over 300,000 people. Rugged Road: Gear up for your next adventure with Rugged Road Coolers - Your ultimate outdoor companion! Head to http://ruggedroadoutdoors.pxf.io/ALLCITY and use code DNVR for 10% off!   Hello Fresh - Get 10 FREE meals at https://hellofresh.com/freebroncos. Applied across 7 boxes, new subscribers only, varies by plan. When you shop through links in the description, we may earn affiliate commissions. Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.

Get your free Muscle-Building Nutrition Blueprint to optimize your diet and tracking so you have the energy and recovery to maximize your lifting–Why did your strength gains stall, and what can you actually do about it? Are you overtrained or just under-recovered? And when is it time to change the program, not your goals?I'm joined by Nick Delgadillo, CEO of Starting Strength Gyms and host of the Stronger Is Better podcast. We break down what really causes lifters to hit that dreaded wall after the novice phase and how to break through it with intention and sustainability. Nick explains why small tweaks, not full overhauls, are key to continued gains and how your form, food, and follow-through matter more than fancy programs.Today, you'll learn all about:2:38 – The psychology of the post-novice wall5:25 – Why recovery outside the gym matters10:23 – Novice vs. intermediate isn't black and white13:11 – How to troubleshoot your progress17:21 – Three-part self-check before changing programming28:26 – Training through tendon pain safely34:59 – Returning to strength after surgery50:15 – How mindset shapes long-term success53:20 – Starting Strength Gyms and the future of liftingEpisode resources:Starting Strength PodcastStronger is Better Podcast on Spotify / Stronger is Better Podcast on AppleWebsite: startingstrengthgyms.comInstagram: @liftfightwin Support the show

Retour sur le premier triathlon de June Où en est Rudy dans ses entrainements ? Que penser de la Reverse diete ? Comment faire un Deload ? Quelle est la différence avec un affutage / tapering ? Que penser des Jammer arms ? ... Retrouvez Rudy Coia et June Lancry pour animer le SuperPhysique Podcast réservés aux pratiquants naturels de musculation. QUI EST RUDY COIA ? Rudy est auteur, coach et formateur. Il intervient aussi bien auprès des particuliers, des athlètes que des futurs coach sportif. Passionné de sport, il partage ses connaissances depuis 2001 notamment via des articles, vidéos et podcasts. QUI EST JUNE LANCRY ? June est coach sportive depuis 2018. Elle a commencé par enseigner et pratiquer le Crossfit, sa première passion, avant de se tourner vers le Bodybuilding naturel dans lequel elle a participé à 2 compétitions en 2022. Elle est particulièrement active sur Instagram sur son compte @junecoach74 et anime le podcast "Beyond Your Why". ---- FORMATION GRATUITE POUR PRATIQUANTS NATURELS - https://www.rudycoia.com/newsletter/ COACHING A DISTANCE AVEC RUDY - https://www.rudycoia.com/produit/suivi-coaching-a-distance/ Le SITE DE JUNE - https://www.junelancry.com MES LIVRES - https://www.rudycoia.com/boutique/ LA FORMATION SUPERPHYSIQUE - https://methodesp.rudycoia.com POUR RESERVER SON COACHING PREMIUM - https://www.rudycoia.com/produit/coaching-premium/ FORUMS SUPERPHYSIQUE - https://www.superphysique.org/forums/index.php MES COMPLEMENTS ALIMENTAIRES - https://www.superphysique.org/nutrition L'APPLICATION SP TRAINING - https://www.sp-training.fr/

The Bulletproof Dental Podcast Episode 399 HOSTS: Dr. Peter Boulden and Dr. Craig Spodak GUEST: Amir Mansouri, SprintRay DESCRIPTION In this episode of the Bulletproof Dental Practice Podcast, Dr. Amir Mansouri, co-founder of SprintRay, shares his journey into 3D dental printing and discusses how this technology is transforming dental practices. The conversation covers the evolution of dental technology, the importance of patient experience, and why practices must adopt 3D printing to stay competitive. Dr. Mansouri also explores the integration of AI in dental design, the role of empowering dental staff, and how these innovations are improving patient care through same-day solutions. TAKEAWAYS SprintRay simplifies 3D printing for dental practices, with Dr. Mansouri's engineering background driving innovation Over 60% of dental practices now use digital solutions like intraoral scanners Night guards are the ideal starting point for practices new to 3D printing Material science challenges are being addressed through Sprint Ray's high ceramic content MIDAS technology The future will see coexistence of milling and printing, with same-day dentistry favoring 3D solutions Entry-level 3D printers now cost around $10,000, while ovens range $10,000-$15,000 AI is simplifying dental design processes and empowering dental assistants Same-day restorations improve patient care and reduce temporary retention issues User-friendly technology is essential for successful staff implementation The dental industry thrives on collaboration and continuous innovation CHAPTERS 00:00 Introduction to Dr. Amir Mansouri and SprintRay 02:01 The Journey into 3D Dental Printing 10:08 Progression of 3D Printing Applications 11:48 The Importance of Patient Experience 13:05 Current State of 3D-Printed Restorations 16:05 Advancements in Material Science 20:52 The Future of 3D Printing in Dentistry 29:10 Understanding the Cost of Dental Technology 35:05 3D Printing in Dentistry: Accessibility and Cost 37:04 The Role of AI in Dental Design 39:55 Empowering Dental Assistants with Technology 44:01 The Future of Dentistry: Innovation and Collaboration   REFERENCES Bulletproof Summit Bulletproof Mastermind

Vous ne savez pas dans quoi investir en Bourse ? Des gérants vous donnent des idées de valeurs, secteurs, matières premières... Aujourd'hui, ce sont Andréa Tueni, sales trader chez Saxo Banque, et David Renan, trader, investisseur et formateur sur DR Bourse.

Montreal Canadiens Defenseman Lane Hutson joined OverDrive to discuss capturing the Calder Trophy, his incredible opening season in the league, representing the Canadiens, enhancing the team for a playoff run, aiming to make the Olympic team for the USA and more.

It's never just an inch...now it has become miles...  

It's never just an inch...now it has become miles...

Did you know that up to 70% of people with prediabetes will go on to develop type 2 diabetes—but only if nothing changes? In this episode, Dr. Jedha breaks down the latest 2025 systematic review that analyzed 59 global studies to identify the strongest predictors of progression from prediabetes to type 2 diabetes. If you've been told you have prediabetes, or you're worried about your blood sugar creeping up, this episode is essential listening. You'll learn which risk factors matter most—including some surprising ones like anxiety and fatty liver—and which ones you can take action on today.You'll come away with science-backed insights and practical next steps to reduce your risk—before type 2 diabetes takes hold.CHAPTERS1:18 Your risk of developing type 2 diabetes, if you do nothing4:36 Sociodemographic risk factors8:12 Lifestyle risk factors12:19 Psychosocial risk factors14:50 Associated health condition risk factors19:31 Top 3 risk factorsFor show notes and resources, please visit: https://Type2DiabetesTalk.comTo share your questions and suggestions, leave us a voice message or email at: https://Type2DiabetesTalk.com/messageExplore our proven programs and services, visit: https://Type2DiabetesTalk.com/programsSubscribe to our free weekly newsletter for podcast updates, valuable nutrition tips and more: https://Type2DiabetesTalk.com/subscribe

SummaryIn this Coaches Roundtable Q&A episode, Chase Smith and Chris Bealhen answer listener questions about fitness, mindset, and nutrition. They kick things off with an inspiring story about an NFL player who walked away from a $30 million contract to stay true to his values. Then, they dive into how to avoid feeling overwhelmed when thinking about working out for life, managing hunger and fullness cues, deciding between cardio and strength training for fat loss, and knowing when to increase your weights in the gym.You'll get practical advice that you can use right away, whether you're new to fitness or a seasoned gym-goer. Plus, Chase and Chris remind us to stay flexible, take breaks when needed, and appreciate the privilege of being able to move our bodies.Chapters(00:00) NFL Player Walks Away from $30 Million(04:00) How to Stay Motivated in the Gym for Life(09:06) Managing Hunger, Fullness, and Meal Timing(16:48) Cardio vs. Strength Training for Fat Burning(23:47) When to Increase Weight vs. Reps in Strength Training(27:36) Final Thoughts and Listener ChallengeSUBMIT YOUR QUESTIONS to be answered on the show: https://forms.gle/B6bpTBDYnDcbUkeD7How to Connect with Us:Chase's Instagram: https://www.instagram.com/changing_chase/Chris' Instagram: https://www.instagram.com/conquer_fitness2021/Facebook Group: https://www.facebook.com/groups/665770984678334/Interested in 1:1 Coaching: https://conquerfitnessandnutrition.com/1on1-coachingJoin The Fit Fam Collective: https://conquerfitnessandnutrition.com/fit-fam-collective

Et si la performance se jouait dans les détails ?Dans cet épisode original de Dans la Tête d'un Coureur, Guillaume et Tristan Pawlak explorent le fascinant concept des gains marginaux : ces petits ajustements qui, cumulés, peuvent transformer votre préparation et vos performances. De l'importance du sommeil à l'optimisation de la foulée, rien n'est laissé au hasard ! Un épisode à la fois pointu et accessible, qui vous donnera des dizaines d'idées simples à intégrer dans votre routine de coureur.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Progression 005 Mix 1 (0:00 - 1:50:56) 01 Manu Pavez - 655 02 Cendryma - Override 03 Benja Molina - Sirio 04 ANUSH - g.o.o 05 ISMAIL.M - Purple Haze (Antonio Farhy Extended Mix) 06 Kyotto - Sorry I'm Late (HAFT Remix) 07 Lucas Pietra - Move 08 ALPHA21 & PASINDU - Tornado (Marchesan Remix) 09 Higgins - Twisted Manouvers 10 Ellroy - Nice To Catch Up 11 Airwave (SL) & SONIDDO - Shout of Whispers (Perc Capsule Remix) 12 Shayan Pasha - Millennium 13 Flex (AR) - Pistas (Rama & Bruno Alonso Remix) 14 Cortona - PeekaBoo 15 Tom Pavicich - Insight (Iovino Remix) 16 SHAZZE, Floyo & JO CRUZ - Rave All Night 17 Randle - Didne (Sabrina Rivas Remix) 18 Randle - Didne Mix 2 (1:50:57 - 3:53:03) 19 Christopher Erre & Greta Meier - Giza (Agustin Pietrocola Remix) 20 Flex (AR) - Do (Seba Benedetti Remix) 21 Agustin Bertolotti - Tablada (Tirso Enríquez AR Remix) 22 Luciano Pelliza & Ger Nogueira - Smoke Sellers 23 Andy Woldman - Rome 24 Andy Woldman - Rome (Zstimer Extended Remix) 25 Tiefstone & CAMILA (AR) - The Range 26 Julieta Kühnle - Full of Nothing (GMJ Remix) 27 Quivver, Dave Seaman - Cowbells of Nuneaton 28 Lucho Bragagnolo - Duality 29 Alfonso G - Mirage 30 Surrender Discipline - Eternity 31 Brisboys - Third Earth (Federico Monachesi Remix) 32 Ben Jad - From Berlin To Africa 33 Praise (BR) - Tornado (Extended Mix) 34 Yohai Mor - Keep It Dark (Matias Ocaño Remix) 35 Nico Sparvieri & Larrosa (AR) - Influences (Mike Griego Remix) 36 Space Food - Famous 37 Allan McLoud - Eminence Return 38 Surrender Discipline - Dusk Till Dawn

June has Ira barking to Joe about various late-spring things in preparation for next week's mandatory minicamp. Enjoy! The wisdom and fun of Ira and Joe is presented by Bill Currie Ford. Click play above or listen at Apple Podcasts or Podbean.com. Many […] The post Ira Kaufman Talks OTA Progression & Overhype, Training Camp Adjustments, Benjamin Morrison, Rookies Under Todd Bowles, Baker Mayfield & The Media, And More appeared first on JoeBucsFan.com.

We start the show with some trash talk from Alabama to Vanderbilt about their next meeting. We then talk about the O-Line and how T'Vondre Sweat and the pass rush will look next year, and how the Titans are prepping for the upcoming year

We talk about wrap-ups from Titans OTAs, talking about the edge rusher position and the end of the 90-man roster with Paul Kuharsky. We also talk about Cam Ward progressing with the wide receivers

Hour Two of the Good Morning Football Podcast begins with hosts Jamie Erdahl, Kyle Brandt, Isaiah Stanback and Jon Robinson answering several questions - will Aaron Rodgers agree to sign with the Steelers? Is Jordan Love progressing enough? Then Jon shares many hilarious stories from his time with NFL organizations.See omnystudio.com/listener for privacy information.

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared to Placebo: The Ekstrom Trial

In this 2023 episode, Jennifer Serravallo explores how The Reading Strategies Book 2.0 is organized to support skill progression and responsive teaching. Learn how the book's “if-then” paths help teachers quickly identify the right strategies based on individual student needs—whether in small groups, whole-class lessons, or intervention settings.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Back in Episode 371, I introduced a perfect storm client case AKA where gut and hormone dysfunction collide and on today's episode, I wanted to extend and expand that conversation. We'll be looking at some potential health issues, key considerations, and more when it comes to being in a deficit, using SHREDS, examining micronutrient status, and more! Topics include: - Compounding Health Issues in a Deficit Phase- Part 2 To The Perfect Storm Client- Key Considerations- Women's Sensitivity to Energy Balance Changes- Iron Status and Deficiencies- Examining SHREDS- Micronutrient Status Considerations- Recapping Common Issues- Preventable Strategies- The FNMS Program---------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠My Live Program for Coaches: The Functional Nutrition and Metabolism Specialization ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.metabolismschool.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- [Free] Metabolism School 101: The Video Series⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.metabolismschool.com/metabolism-101⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------Subscribe to My Youtube Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@sammillerscience?si=s1jcR6Im4GDHbw_1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grab a Copy of My New Book - Metabolism Made Simple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- Stay Connected: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube: SamMillerScience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: The Nutrition Coaching Collaborative Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ----------“This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast and the show notes or the reliance on the information provided is to be done at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for educational purposes only. Always consult your physician before beginning any exercise program and users should not disregard, or delay in obtaining, medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. By accessing this Podcast, the listener acknowledges that the entire contents and design of this Podcast, are the property of Oracle Athletic Science LLC, or used by Oracle Athletic Science LLC with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of Oracle Athletic Science LLC, which may be requested by contacting the Oracle Athletic Science LLC by email at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠operations⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@sammillerscience.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. By accessing this Podcast, the listener acknowledges that Oracle Athletic Science LLC makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast."

Tenor saxophonist Rich Perry might be most recognized from his long term associations with both the Maria Schneider and Vanguard Jazz Orchestras, but where he truly shines is fronting his quartet with pianist Gary Versace, bassist Jay Anderson, and Vanguard band mate John Riley on drums and cymbals. In this episode of LINER NOTES we discuss the music and musicians on Progression, his fourth recording on the Steeplechase label with this line-up.  

It's important to know the progression of muscle fiber dysfunction to better understand how to treat and how long it may take to correct the problem.   The analysis of current research provides substantial evidence supporting the progression of muscle fiber dysfunction as a significant contributor to musculoskeletal pain, aligning with the hypothesized sequence: sustained muscle tone leading to long-term muscle fiber shortening, which subsequently culminates in painful myofascial trigger points. The initial phase of this progression is rooted in the transition from normal physiological muscle tone to a state of pathological hypertonia or chronic muscle overload. Sustained low-level muscle contractions, even at submaximal levels, are shown to generate sufficient intramuscular pressure to compromise local capillary blood flow. This circulatory impairment leads to localized ischemia and hypoxia within the muscle fibers, precipitating a critical "energy crisis" due to insufficient ATP production. This energy deficit is pivotal for the subsequent development of muscle fiber shortening. ATP is indispensable not only for muscle contraction but also for the crucial process of muscle relaxation, specifically for the detachment of myosin heads from actin and the re-uptake of calcium ions. When ATP is depleted, these relaxation mechanisms fail, resulting in sarcomeres becoming locked in a state of sustained, pathological hypercontraction. This localized shortening at the sarcomere level forms the palpable "taut band" that is a hallmark of myofascial trigger points. Over extended periods, such sustained pathological shortening can also contribute to broader structural changes like muscle contractures, involving fibrosis and a permanent reduction in muscle length. The culmination of this progression is the development of painful trigger points. The sustained sarcomere hypercontraction, driven by the energy crisis and calcium dysregulation, creates a severely acidic local environment. This acidic milieu, coupled with tissue injury from prolonged ischemia, triggers the release and accumulation of various neuroactive and inflammatory mediators. These substances directly stimulate and sensitize muscle nociceptors, manifesting as the exquisite tenderness and characteristic referred pain associated with active myofascial trigger points. Furthermore, the pathophysiology of myofascial trigger points is characterized by a complex, self-perpetuating vicious cycle. The energy crisis and subsequent acidic environment inhibit acetylcholinesterase, leading to prolonged acetylcholine effects and further sustained muscle contraction. Concurrently, mediators like calcitonin gene-related peptide (CGRP) not only potentiate muscle contraction but also directly activate nociceptors. This intricate feedback loop ensures the chronicity of the condition, as the consequences of muscle shortening directly exacerbate the initial problem of sustained contraction and pain. This comprehensive understanding of the progression from sustained muscle tone to muscle shortening and painful trigger points has significant implications for both clinical practice and future research in musculoskeletal pain. For clinicians, it underscores the importance of early identification and intervention for chronic muscle tension and overuse, aiming to disrupt the energy crisis cycle before fixed structural changes or chronic pain states become entrenched. Therapeutic strategies should not only target pain relief but also address the underlying metabolic and biomechanical dysfunctions, including restoring proper muscle length, improving local circulation, and resolving the energy deficit. For researchers, the identified roles of specific molecules like CGRP and the intricate feedback loops within the "energy crisis" model present promising avenues for developing novel diagnostic markers and targeted pharmacological or rehabilitative interventions that can effectively break the self-perpetuating cycle of myofascial pain.   Online Courses: https://richardhazel.podia.com    

Hey mission fam! In episode 206 - The Benefits of a Holding Pattern, I'm diving deep into the concept of a "holding pattern" - something we often judge ourselves for, but which can actually be incredibly powerful and necessary. I share how these periods of seeming stillness aren't about procrastination or laziness, but can be sacred spaces of healing, regrouping, and intentional preparation. Drawing from aviation analogies and personal experiences (like President Utchdorf), I explore how holding patterns protect us from rushed decisions and give us time to reconnect with ourselves and God. Whether you're a missionary going through the motions, a returned missionary processing your experience, or someone waiting on a big life decision, this episode will help you see these moments not as setbacks, but as valuable parts of your growth journey. I wrap up by sharing a beautiful scripture from Psalms - "Rest in the Lord and wait patiently for Him" - and encourage listeners to view their holding patterns as intentional, holy spaces. My hope is that you'll walk away with more compassion for yourself and understanding that you're always progressing, even when it doesn't look like forward movement. As always, if you found this episode helpful, I want to invite you to subscribe if you aren't already, share this episode with your friends and missionaries you know, and write a review. I know this work will help LDS missionaries around the world and it would mean so much to me if you did. Until next week my friends.   Website | Instagram | Facebook   Get the Full Show Notes and Text/PDF Transcripts: HERE   Free PDF Download:  Podcast Roadmap   Free PDF Download:  Preparing Missionary Cheat Sheet   Free Training for Preparing Missionaries:  Change Your Mission with this One Tool   RM Transition Free Video Series:  3 Tools to Help RMs in Their Transition Home   Free Guide:  5 Tips to Help Any Returning Missionary   Schedule a Free Strategy Call:   Click Here  

Maintaining Gains Post Cycle, Managing labs on orals, Recovering From Thyroid Meds, Depression from Tren? @KubaSylvesterCielen and Scott McNally 2:00 Post Cycle Low Points - Whatever comes up, must come down 7:00 Dopamine Hits From Alternative Activities 9:30 Why Females May Struggle More Post Cycle 13:00 Supplements to consider post cycle 23:00 SLU-PP-332 Between Cycles 25:30 Growth Hormone Between Cycle and in PCT 29:00 Tips after recovery from Thyroid Meds 32:00 Where should your estrogen level be on cycle? 42:30 Orals and Labs 44:00 Favorite Orals 48:00 Progression for an older athlete 54:15 Depression on tren 59:30 Kuba's Prep ✅ Follow the guys here : https://www.instagram.com/kuba_sylvester_cielen/ https://www.instagram.com/scottmcnally1/

There are three types of players or individuals in the world that coaches need to work with. DR L discusses the importance of mindset vs. talent in building legacies and long-term success for not only teams but for us each as individuals.

New York state debates assisted suicide legislation, the killing of two Israeli embassy staffers, and four pianos and thirty players. Plus, Hunter Baker on protecting religious freedom, and the Tuesday morning newsSupport The World and Everything in It today at wng.org/donate.Additional support comes from BibleStock.org. Helping Bible teachers bring the land of the Bible to life through photos and videos. BibleStock.org

Come to OUR FIRST EVER EXPERIENCE! https://brushfire.com/wholewomanco/utwwwco/603899Members get Eps 2 Days early, vlogs, & exclusive STREAMS! Join today!https://www.youtube.com/channel/UCqzgGwRrOLH20OIc8bM_VAg/joinCOME SEE TIM DO COMEDY - Get Tickets Here https://linktr.ee/timross(Tim's Lip Balm) - GlowSkin Care - https://www.facebook.com/AllNaturalOrganicProductsMadeWithLove/

Welcome to PTs Snacks podcast! I'm Kasey, your host, and today we're diving into chronic workload ratios—an essential tool to manage injury risk in athletes. We'll break down the formula, discuss ideal ratio zones, and use examples like running, strength training, and RPE to showcase its application. This episode is perfect for physical therapists and students looking to apply this concept in various settings, from clinics to personal workouts. Tune in to learn how to quantify safe progressions and keep your athletes at their best!00:00 Introduction to PTs Snacks Podcast00:35 Understanding Chronic Workload Ratio02:56 Calculating the Chronic Workload Ratio04:09 Ideal Zones and Examples07:56 Practical Applications for PTs09:13 Additional Resources and ConclusionSupport the showWhy PT Snacks Podcast?This podcast is your go-to for bite-sized, practical info designed for busy, overwhelmed Physical Therapists and students who want to build confidence in their foundational knowledge without sacrificing life's other priorities. Stay Connected! Never miss an episode—hit follow now! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. Join the email list HERE On Instagram? Find unique content at @dr.kasey.hankins! Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less!(These are affiliate links, but I only recommend Medbridge because it's genuinely valuable.) Optimize Your Patient Care with Tindeq Looking for a reliable dynamometer to enhance your clinical measurements? Tindeq ...

Reed Wommack shares his journey into Bitcoin, transitioning from a role at Swan Bitcoin to running Groundluxe, a company focused on grounding products. He discusses the evolving landscape of Bitcoin treasury companies, the risks and rewards associated with leveraging debt for investments, and the importance of a long-term perspective in navigating market cycles. Reed also emphasizes the potential for Bitcoin to dominate the equity market and the impact of capital gains tax on investment strategies. He encourages listeners to consider their risk profiles when adopting aggressive investment strategies.Takeaways

The first American pope, Leo XIV, is making waves by unapologetically restoring traditional Catholic doctrine on marriage, family, and the dignity of life. His early remarks have sparked outrage among progressive activists, but they also mark a sharp turn away from the ambiguities of the Francis papacy. We're going to see the historical and theological roots of Pope Leo's views, exposing the irony of modern progressives advocating for pre-Christian values under the guise of "inclusion."--Head to http://twc.health/turley and use code TURLEY to SAVE $90 off plus Free Shipping *The content presented by sponsors may contain affiliate links. When you click and shop the links, Turley Talks may receive a small commission.* Head over to https://turley.pub/VegasGoesBitcoin and reserve your seat today. I'll see you there!Highlights:“Pope Leo affirmed that the family is founded on ‘the stable union between a man and a woman', and that the unborn and elderly enjoy dignity as God's creatures, articulating clear Catholic teaching on marriage and abortion at the start of his pontificate.”“Woke activists are, in point of fact, the regressives. They are the ones who want to return to the darkness of a world closed off from the heavenly life that has broken into our world in and through Christ and his body, the church.”“Progression always, by definition, involves return, as time itself is increasingly transfigured by the light of eternal and everlasting glory.”Timestamps: [01:07] Pope Leo XIV's first statements on marriage and life[04:36] Media and activist backlash to traditional doctrine [06:50] The contrast between Greco-Roman and Christian views on gender and family[11:00] Why true progress lies in a return to eternal truths--Thank you for taking the time to listen to this episode. If you enjoyed this episode, please subscribe and/or leave a review.FOLLOW me on X (Twitter): https://twitter.com/DrTurleyTalksSign up for the 'New Conservative Age Rising' Email Alerts to get lots of articles on conservative trends: https://turleytalks.com/subscribe-to-our-newsletter**The use of any copyrighted material in this podcast is done so for educational and informational purposes only including parody, commentary, and criticism. See Hosseinzadeh v. Klein, 276 F.Supp.3d 34 (S.D.N.Y. 2017); Equals Three, LLC v. Jukin Media, Inc., 139 F. Supp. 3d 1094 (C.D. Cal. 2015). It is believed that this constitutes a "fair use" of any such copyrighted material as provided for in section 107 of the US Copyright Law.

Philadelphia Flyers Head Coach Rick Tocchet joined OverDrive to discuss his hiring with the Flyers, leading the team as a coach, the landscape in Philadelphia on the roster, the departure from Vancouver and the experience in a Canadian market, the progression of the team and more.

In this episode, I'm thrilled to welcome back Dr. Aaron Boster, he is a board-certified Neurologist specializing in Multiple Sclerosis and related CNS inflammatory disorders. Dr. Boster joins me to share his powerful ‘5 for 5' framework—five essential strategies to slow MS progression and improve your quality of life with multiple sclerosis. We break down each pillar: smoking cessation, exercise, nutrition, mindfulness, and choosing the most effective disease-modifying therapy. Dr. Boster offers practical advice that's easy to understand and apply, covering everything from hydration tips and vitamin D to how to make exercise a sustainable part of your MS lifestyle. If you're looking for expert MS management strategies, actionable exercises, and ways to support your MS journey, you won't want to miss this empowering conversation! Tune in for clear, actionable tips to take control of your MS and live your best life. About Dr. Aaron Boster: Aaron L Boster, MD, is a board-certified clinical neuroimmunologist specializing in Multiple Sclerosis. As a neuroimmunologist, Dr Boster provides diagnosis and treatment for all types of MS as well as a wide range of neuroimmunological conditions. He also provides medical management of refractory severe spasticity with expertise in intrathecal baclofen. Dr. Boster received his undergraduate degree from Oberlin College in Oberlin, Ohio and his medical degree from the University of Cincinnati College of Medicine in Cincinnati, Ohio. Dr Boster completed his internship and neurology residency through the University of Michigan in Ann Arbor, Michigan. He continued his training at Wayne State University in Detroit, Michigan, where he completed a fellowship focused on clinical neuroimmunology and multiple sclerosis. He has over a decade and a half of experience combating MS in the clinic and participating in MS clinical research. Connect with Dr. Aaron Boster: Twitter: https://twitter.com/aaronbostermd Youtube: https://www.youtube.com/c/AaronBosterMD Facebook: https://www.facebook.com/AaronBosterMD/ Website: https://bosterms.com/ Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink